What is the official website of SHIMADZU CORPORATION ?

The official website of SHIMADZU CORPORATION is http://www.shimadzu.com.

What is SHIMADZU CORPORATION's cybersecurity risk score?

SHIMADZU CORPORATION has an AI-generated cybersecurity risk score of 759 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has SHIMADZU CORPORATION experienced?

According to Rankiteo, SHIMADZU CORPORATION currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has SHIMADZU CORPORATION been affected by any supply chain cyber incidents ?

According to Rankiteo, SHIMADZU CORPORATION has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does SHIMADZU CORPORATION have SOC 2 Type 1 certification ?

According to Rankiteo, SHIMADZU CORPORATION is not certified under SOC 2 Type 1.

Does SHIMADZU CORPORATION have SOC 2 Type 2 certification ?

According to Rankiteo, SHIMADZU CORPORATION does not hold a SOC 2 Type 2 certification.

Does SHIMADZU CORPORATION comply with GDPR ?

According to Rankiteo, SHIMADZU CORPORATION is not listed as GDPR compliant.

Does SHIMADZU CORPORATION have PCI DSS certification ?

According to Rankiteo, SHIMADZU CORPORATION does not currently maintain PCI DSS compliance.

Does SHIMADZU CORPORATION comply with HIPAA ?

According to Rankiteo, SHIMADZU CORPORATION is not compliant with HIPAA regulations.

Does SHIMADZU CORPORATION have ISO 27001 certification ?

According to Rankiteo,SHIMADZU CORPORATION is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does SHIMADZU CORPORATION operate in ?

SHIMADZU CORPORATION operates primarily in the Biotechnology Research industry.

How many employees does SHIMADZU CORPORATION have ?

SHIMADZU CORPORATION employs approximately 1,832 people worldwide.

Does SHIMADZU CORPORATION own any subsidiaries ?

SHIMADZU CORPORATION presently has no subsidiaries across any sectors.

How many LinkedIn followers does SHIMADZU CORPORATION have ?

SHIMADZU CORPORATION's official LinkedIn profile has approximately 55,826 followers.

What is the NAICS classification code for SHIMADZU CORPORATION ?

SHIMADZU CORPORATION is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does SHIMADZU CORPORATION have a Crunchbase profile ?

No, SHIMADZU CORPORATION does not have a profile on Crunchbase.

Does SHIMADZU CORPORATION have a LinkedIn profile ?

Yes, SHIMADZU CORPORATION maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/shimadzu-corporation.

How many cybersecurity incidents has SHIMADZU CORPORATION experienced ?

As of September 3, 2026, Rankiteo reports that SHIMADZU CORPORATION has not experienced any cybersecurity incidents.

How many peer or competitor companies does SHIMADZU CORPORATION have ?

SHIMADZU CORPORATION has an estimated 4,755 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

SHIMADZU CORPORATION

Boost Score +25 with badge (5 left)

759

/1000

Fair

784

/1000

Fair

SHIMADZU CORPORATION Vendor Cyber Rating & Cyber Score

shimadzu.com

Add Your Compliance Badge

Shimadzu Corporation has remained committed to commercializing cutting-edge technology and providing it to customers in a wide array of industries for more than 150 years. Our brand statement, "Excellence in Science", reflects our desire and attitude to diligently respond to customers' requirements by offering superior, world-class analytical and measuring instruments, medical imaging systems, aircraft equipment and industrial machinery for the advancement of human health, the safety and security of society, and industrial processes. In today’s challenging, ever-changing landscape, Shimadzu aims to partner with customers to meet their needs with unique technologies and solutions.

SHIMADZU CORPORATION A.I CyberSecurity Scoring

Scoring History

SHIMADZU CORPORATION

SHIMADZU CORPORATION CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

SHIMADZU CORPORATION Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for SHIMADZU CORPORATION

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for SHIMADZU CORPORATION in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for SHIMADZU CORPORATION in 2026.

Incident Types SHIMADZU CORPORATION vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for SHIMADZU CORPORATION in 2026.

Incident History - SHIMADZU CORPORATION (X = Date, Y = Severity)

Loading…

SUBSIDIARY

SHIMADZU CORPORATION Subsidiaries

Parent Company

SHIMADZU CORPORATION

Biotechnology Research

Website: http://www.shimadzu.com

Company Size: 10,001+ employees

No subsidiary data available for this company.

Loading…

SHIMADZU CORPORATION Similar Companies

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

Gilead Sciences

cb gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Genentech

gene.com

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Loading…

NEWS

SHIMADZU CORPORATION CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

September 10, 2025 07:00 AM

Kinaxis (TSX:KXS) Chosen by Shimadzu Corporation to Enhance Global Supply Chain Strategy

Kinaxis saw a slight stock movement over the last week, coinciding with its recent partnership announcement with Shimadzu Corporation.

Read Article

June 01, 2023 07:27 AM

Shimadzu's New Nexera Mikros Microflow LC-MS-MS System Balances High Sensitivity with Ruggedness and Elegant Design

COLUMBIA, Md. (February 22, 2018) — Shimadzu Scientific Instruments (SSI) announces the release of the Nexera Mikros Microflow Liquid Chromatography Mass...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-84857

SUMMARY

A flaw has been found in sigoden aichat up to 0.30.4. This affects an unknown function of the file src/serve.rs of the component API Endpoint. This manipulation causes uncontrolled memory allocation. The attack can be initiated remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:N/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-84856

SUMMARY

A vulnerability was detected in rowboatlabs rowboat up to 0.9.1. The impacted element is the function request.text/req.json of the file apps/rowboat/app/api/composio/webhook/route.ts of the component Composio Webhook Endpoint. The manipulation results in denial of service. It is possible to launch the attack remotely. The exploit is now public and may be used. Upgrading to version 0.9.2 is sufficient to resolve this issue. Upgrading the affected component is recommended. The legacy Next.js app was deleted at 0.9.2 rather than patched, leaving no security control behind.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:N/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-84852

SUMMARY

A security vulnerability has been detected in Reader Tools PDF Reader App 98.8 on Android. The affected element is the function ActSplashNew.handleDeeplink of the component File Handler. The manipulation of the argument _display_name leads to path traversal. An attack has to be approached locally. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 4.4)

cvss2

Base Score: 3.2

Complexity: LOW

AV:L/AC:L/Au:S/C:N/I:P/A:P

cvss3

Base Score: 4.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

1.8

REFERENCES

CVE-2026-84452

SUMMARY

Windows ML CLI is a command line tool for building portable, performant, and high-quality AI models for Windows ML. Prior to 0.4.0, the src/winml/modelkit/serve/cli_api.py component exposes WinML CLI commands through a localhost HTTP API without authentication and configures the allow_origins setting as a wildcard in both src/winml/modelkit/serve/cli_api.py and src/winml/modelkit/serve/app.py. A malicious website loaded by a user can send cross-origin requests to /v1/cli/build or /v1/cli/config and set the trust_remote_code parameter to true, which is converted to the --trust-remote-code command-line flag without validation. This reaches AutoConfig.from_pretrained with trust_remote_code=True in src/winml/modelkit/loader/_autoconfig.py and imports Python code from an attacker-controlled model repository, resulting in arbitrary code execution as the server user. This issue is fixed in version 0.4.0.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: )

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-84292

SUMMARY

fast-uri serializes the port component of a URI without validating it. When recomposing the authority, the userinfo and host components are escaped but the port is concatenated verbatim, so a port value that is not a sequence of digits can inject authority delimiters, demoting the intended host to userinfo and pointing the authority at an attacker-controlled host. Both fast-uri and Node's URL read the result back as the attacker's host with no error, so re-validating the built URI does not catch it. This affects applications that build URIs from parts and assign untrusted data to the port component through the serialize, normalize, or equal functions in their object forms. The issue affects fast-uri versions before 2.4.6, from 3.0.0 before 3.1.7, and from 4.0.0 before 4.1.4. It is fixed in 2.4.6, 3.1.7, and 4.1.4, where recomposeAuthority rejects any port that is not a digit sequence per RFC 3986.

Published

Date2026-09-02

Updated

Date2026-09-02

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…